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ABSTRACT 
Human platelets aggregate at sites of blood vessel damage in response to a rise in their cytosolic calcium concentration. 
Controlling these cytosolic calcium rises would provide a method to inhibit platelet activation and prevent the unwanted blood clots 
that causes heart attack and strokes. Previously we have predicted that calcium accumulation within the lumen of an infolded 
portion of the platelet plasma membrane called the open canalicular system (OCS) is essential for maintaining this cytosolic 
calcium rise. Due to its nanometer dimensions of the OCS, it has been difficult to measure or interfere with the predicted luminal 
calcium accumulation. Here we utilise iron oxide magnetic nanoparticles coated with the known calcium chelator, citrate, to create 
calcium-binding nanoparticles. These were used to assess whether an OCS calcium store plays a role in controlling the dynamics 
of human platelet activation and aggregation. We demonstrate that citrate-coated nanoparticles are rapidly and selectively uptaken 
into the OCS of activated human platelets, where they act to buffer the accumulation of calcium there. Treatment with these 
calcium-binding nanoparticles reduced thrombin-evoked cytosolic calcium rises, and slowed platelet aggregation and clot 
retraction in human platelets. In contrast, nanoparticles that cannot bind calcium have no effect. This study demonstrates that the 
OCS acts as a key source of calcium for maintaining cytosolic calcium rises and accelerating platelet aggregation, and that 
calcium-binding nanoparticles targeted to the OCS could provide an anti-platelet therapy to treat patients at risk of suffering heart 
attacks or strokes. 
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1 Introduction 
Human platelets are small, discoid, anucleate cells that orchestrate 
blood clotting at sites of blood vessel injury [1]. Clot formation 
is a multi-step process involving platelet adhesion to the 
damaged vessel wall, the recruitment of circulating platelets 
to form a platelet aggregate to block the hole in the vessel, 
activation of the blood coagulation to produce fibrin to 
strengthen the clot, and finally clot retraction to tightly seal 
the hole in the blood vessel wall [2]. Every one of these stages 
of platelet activation are triggered by rises in cytosolic calcium 
concentration ([Ca2+]Cyt). These calcium rises are triggered by 
thrombin and collagen (which are exposed in the wall of the 
damaged blood vessel) binding to receptors on the platelet 
surface. The activated receptors then initiate an intracellular 
signalling cascade that results in a rapid increase in the [Ca2+]Cyt 
to trigger platelet activation and aggregation [3]. This central 
role for calcium in triggering the early events underlying 
blood clotting has led researchers to identify ways to inhibit 
cytosolic Ca2+ rises as a route to creating anti-platelet drugs 
that prevent platelet activation to protect against the unwanted 
blood clotting that occurs in patients suffering heart attacks 
and strokes [4]. 
One of the most striking features of human platelet 
ultrastructure is the open canalicular system (OCS), a system 
of invaginations of the plasma membrane that creates an 
elaborate series of tunnels through the platelet interior that 
are continuous with the extracellular fluid. However due to the 
complex geometry of the tunnel network, as well as its tiny 
lumen diameter (20–30 nm) [5], it has only been possible to 
study this structure by electron microscopy. This has led to the 
OCS being considered principally for its structural contributions 
to platelet activation, such as a site for granule fusion or as 
a membrane reservoir to allow shape change [6], membrane 
tether formation [7], or to facilitate platelet spreading over 
the subendothelial matrix [8]. Previously we showed that 
this structure may also play an important role in controlling 
platelet activation by acting as a dynamic Ca2+ store that can 
be recycled back into the platelet cytosol through Ca2+- 
permeable ion channels [9]. By potentiating and prolonging 
cytosolic Ca2+ signals this store might play a key role in 
regulating human platelet activation and aggregation [9]. We 
hypothesised that compounds that prevent Ca2+ storage within 
the OCS could slow platelet activation and therefore limit 
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blood clotting. However due to the difficulty of assessing the 
chemical environment within the OCS in live platelets, a 
new experimental approach is required to examine whether 
Ca2+ rises within the OCS played a role in controlling human 
platelet activation and aggregation. 
Iron oxide nanoparticles (IONPs) are bio-compatible 
magnetic particles that have been widely studied as potential 
theranostic agent. Due to their relatively simple synthesis [10], 
easily tunable physico-chemical properties [11], cheap cost of 
production [12] and minimal toxicity [13], a diverse range of 
IONP-based biomedical therapies and diagnosis approaches 
have been proposed in recent decades [14]. Owing to their 
nanometre size, IONPs are small enough to enter the OCS where 
they could be used to sense or alter the chemical environment. 
IONPs are commonly coated with citric acid to create a charged 
surface that allows them to be stable in polar solutions [15]. 
As citric acid is also an effective Ca2+-chelating agent that is 
commonly used in blood anti-coagulants [16], we hypothesized 
that citrate-coated IONPs could be utilized to create Ca2+ 
nanochelators that could enter the OCS lumen and buffer 
thrombin-evoked rises here. This would allow us to test the 
hypothesis that increases in Ca2+ concentration within the OCS 
are important in regulating human platelet activation.  
In this paper, we produce calcium-binding IONPs and assess 
their ability to inhibit thrombin-evoked Ca2+ signalling and 
platelet activation. Through these experiments, we provide the 
first direct evidence that the OCS plays a key role in regulating 
Ca2+ signalling in human platelets, and that calcium-binding 
nanoparticles targeted to the OCS could be used to create novel 
anti-thrombotic drugs to prevent blood clotting in patients at 
risk of heart attacks and strokes. 
2  Results and discussion 
2.1  Characterisation of the physical properties of the 
IONPs 
Prior to assessing their effect on human platelets, the physical 
and chemical properties of the IONPs used in this study were 
characterised with transmission electron microscopy (TEM) 
and dynamic light scattering-electrophoretic light scattering 
(DLS-ELS). These include citric acid-coated maghemite IONPs 
that were prepared in our labs (Cit/1-IO), as well as commercially- 
available citric acid-(Cit/2-IO) and amine-functionalised 
polyethylene glycol-coated (PEG-IO) IONPs. The PEG-coated 
IONPs were used to provide a comparison of the effects studied 
when the nanoscale dimensions were maintained, but the 
citric acid chelator was replaced with a non-chelating polymer 
surface coating.  
Figure 1(a) shows representative TEM images of the Cit/1-IO, 
Cit/2-IO and PEG-IO nanoparticles. All three nanoparticle 
sets showed a rounded morphology and had measured core 
sizes of less than 20 nm (Cit/1-IO = 15 ± 4 nm, Cit/2-IO = 9 ± 
4 nm and PEG-IO = 10 ± 4 nm; (Fig. S1 in the Electronic 
Supplementary Material (ESM)). All of the IONP samples also 
exhibited comparable hydrodynamic sizes (DH) when dispersed 
in double-distilled water (ddH20; 57, 62 and 75 nm for Cit/1-IO, 
Cit/2-IO and PEG-IO respectively; Fig. S1 in the ESM). As 
expected, the zeta potential (ζ) of these IONPs varies strongly 
depending on the IONPs coating, with citrate-coated IONPs 
being highly negatively charged (Cit/1-IO = –51.8 ± 0.4 mV 
and Cit/2-IO = –50.5 ± 0.2 mV), whereas the PEG-IO showed 
positive charge (+37.6 ± 0.5 mV). These values are in agreement 
with previously reported ζ values of particles coated with similar 
compounds and obtained from similar sources [17–19]. 
 
Figure 1  Characterisation of morphological and Ca2+-chelating properties 
of the IONPs. (a) Representative TEM images of Cit/1-IO, Cit/2-IO and 
PEG-IO nanoparticles. (b) Assessing the Ca2+ chelation properties of IONP 
samples. Equal concentrations of Cit/1-IO, Cit/2-IO and PEG-IO nanoparticles 
were added to a deionised water sample containing 250 μM EGTA and 3 μM 
Fura-2 pentapotassium salt held at 37 °C. Step-wise addition of known 
concentrations of CaCl2 were added to this EGTA-buffered solution and the 
free [Ca2+] was calculated using the MaxChelator program. Fura-2 fluorescence 
was measured at each extracellular [Ca2+] concentration, and normalised to % 
maximum of fluorescence measured in saturating Ca2+ concentrations.   
(c) Hydrodynamic size and (d) zeta potential measurements of the IONPs 
when suspended in solutions with different Ca2+ concentrations. 
2.2  Characterisation of the Ca2+-binding capacity of 
IONPs 
Citric acid is a widely-used anti-coagulant due to its Ca2+ 
chelating properties, however the ability of citrate-coated 
nanoparticles to effectively chelate Ca2+ has not been previously 
demonstrated. Experiments were performed to assess whether 
the citrate-coated IONPs were able to buffer Ca2+ levels in 
EGTA-buffered CaCl2 solutions containing the fluorescent 
Ca2+ indicator, Fura-2. IONP suspensions were added to the 
solution such that there was an equal concentration of iron 
(300 μM) in each sample, as measured by a ferrozine assay. 
Stepwise addition of known amounts of CaCl2 were added to the 
suspension, and the resultant increase in Fura-2 fluorescence 
was measured to assess the Ca2+ buffering abilities of the 
IONPs samples. The PEG-coated IONPs were used as a 
negative control to show the response from IONPs that do not 
bind Ca2+. As can be observed in Fig. 1(b), the commercially- 
sourced Cit/2-IO particles were not notably better at chelating 
Ca2+ in comparison to the PEG-coated particles, as there were 
similar increases in the Fura-2 fluorescence of the samples 
since the free [Ca2+] of the solution was increased. In contrast, 
the citrate-coated IONPs made in house were found to 
significantly reduce the increase in the Fura-2 fluorescence 
relative to its maximum value—suggesting that the citrate 
coating of this particle allows it to act as an effective Ca2+ 
chelator.   
Further experiments were performed to examine the 
differential Ca2+ chelating capacity of the Cit/1-IO and Cit/2-IO 
nanoparticles. To assess if the different Ca2+-binding capacities 
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were due to differences in the stability of these IONPs in 
solutions of different Ca2+ concentrations, measurements of ζ 
potential and hydrodynamic size (DH) were also performed 
when the IONPs were dispersed in solutions with a variety of 
Ca2+ concentrations. As can be seen in Fig. 1(c), the negative ζ 
potential of the Cit/2-IO particles rapidly decreased as the 
external Ca2+ concentration was increased into the micromolar 
range. In contrast, the Cit/1-IO maintained their ζ potential 
until the external Ca2+ concentration reached millimolar levels. 
Both Cit/1-IO and Cit/2-IO reached near zero ζ potentials at 
high millimolar levels suggesting that both particles have their 
negatively charged surfaces modulated by Ca2+, but requiring 
orders of magnitude different Ca2+ concentrations to do so. 
This difference in the reduction of the ζ potentials of the 
IONPs correlated with differences in the Ca2+ sensitivity of the 
DH  of the IONPs, with DH of the particles starting to increase 
at lower Ca2+ concentrations in Cit/2-IO IONPs than Cit/1-IO 
(Fig. 1(d)).  
In contrast, PEG-coated particles showed only minimal 
difference in ζ potentials and DH as external Ca2+ concen-
tration increased, suggesting this property is due to the 
differences in the surface coating of the IONPs and not the 
chemical composition of the IONP core. Our experiments 
show that the Cit/2-IO particles are prone to agglomeration 
when extracellular Ca2+ concentration is raised into the 
micromolar range, whilst the Cit/1-IO particles are stable in 
solution until millimolar Ca2+ concentrations. These data suggest 
that the greater Ca2+ sensitivity of the Cit/2-IO IONPs leads 
to their rapid aggregation when placed in Ca2+-containing 
solutions. This would lower the effective surface area of these 
citrate-coated particles available for Ca2+ binding. It appears 
that it is this inability to maintain an effective surface area in 
Ca2+-containing solutions that ultimately impairs their chelation 
capacity. The method of coating the magnetic nanoparticles 
with citric acid strongly determines the efficacy and stability 
of the grafting of this molecule to the nanoparticle surface. 
This will control the density, orientation and charge of citric 
acid coating on the nanoparticle surface, which could alter 
the nanoparticles calcium-binding capacity and stability in 
Ca2+-containing solutions. The Cit/1-IO nanoparticles were 
coated with citric acid using the optimised method described 
by Campelj et al. [2], and it is therefore possible that different 
coating methods used for the Cit/1-IO and the commercially- 
produced Cit/2-IO nanoparticles underly the discrepancy 
observed here through altering the effective surface density 
of citric acid on the surface of the nanoparticles. Alternatively 
citric acid may coat differently on the maghemite Cit/1-IO 
and magnetite Cit/2-IO nanoparticles. A comprehensive study 
of the conditions used to coat the nanoparticles with citric 
acid will be required to allow us to optimise the stability and 
calcium-binding capacity of the citrate-coated nanoparticles 
for use as an anti-platelet agent.     
2.3  Activation-dependent incorporation of citrate-coated 
IONPs into the OCS of human platelets  
TEM experiments were performed to assess if the IONPs 
could be incorporated into the OCS of human platelets. 
Platelet samples were prepared for TEM by incubating them for 
10 min at 37 °C with the Cit/1-IO or Cit/2-IO nanoparticles. 
Samples were then either fixed directly, or stimulated for 1 min 
with thrombin and then fixed, to see if unstimulated and/or 
activated platelets could take up these IONPs into the OCS.  
Due to the lumen of the OCS having a diameter of around 
20–30 nm in a resting platelet, they can only be observed 
through electron microscopy. In transmission electron 
microscopy images the OCS appears as irregularly-shaped, 
clear vacuoles occurring within the platelet interior, due to the 
inability of the extracellular fluid contained within the lumen 
to absorb or scatter electrons [5–8]. In contrast, the various 
platelet granules appear as electron dense structures of more 
regular size and shape. These structures are clearly observed 
in the unstimulated platelets as shown by red (OCS) and blue 
(Granules) arrows in Figs. 2(a) and 2(c).  In the unstimulated 
platelets, it was observed that there was almost no uptake of 
any of the IONPs into the OCS, with any remaining IONPs 
after sample washing being found only in regions external to 
the platelet plasma membrane (Figs. 2(a) and 2(c)). This was 
consistent with the previous findings of Escolar et al. [8], who 
demonstrated that fibrinogen-coated gold nanoparticles do 
not permeate into the resting platelet.  
In thrombin-activated platelets, the platelets begin to spread 
and lose their discord form and platelet granules are secreted, 
leading to these structures becoming less numerous inside the 
activate platelet (Figs. 2(b) and 2(d)). OCS channels also can 
become dilated as this structure reorganizes itself (Fig. S2 in 
the ESM). Thrombin-activated platelets were seen to have  
significant uptake of IONPs into the OCS. No nanoparticles 
were seen to be endocytosed into the remaining platelet 
granules (blue arrows; Figs. 2(b) and 2(d)). Instead both the 
Cit/1-IO and Cit/2-IO nanoparticles could predominantly be 
seen to densely accumulate within the lumen of the OCS—as 
seen by the low electron density and irregular shapes of the 
compartments (Magnified boxes; Figs. 2(b) and 2(d)). Additionally, 
closer examination of some of the electron microscope images 
showed particles in sections of the OCS connected via the 
pore region to the surface of the surface membrane (Figs. 2(a), 
2(b) and 2(d); Green Arrows). A small amount of Cit/1-IO 
 
Figure 2  Citrate-coated IONPs are selectively and rapidly uptaken into 
the OCS of thrombin-stimulated platelets. Representative TEM images of 
platelets incubated with ((a) and (b)) Cit/1-IO and ((c) and (d)) Cit/2-IO 
nanoparticles at [Fe] = 300 μM at 37 °C for 10 min. Platelets in (a) and (c) 
were fixed whilst resting whereas in (b) and (d) were activated with  
0.5 U/mL thrombin for 1 min before fixation. The OCS lumen are 
distinguishable from other subcellular regions as they appear to have a clear 
interior due to their continuity with the bulk extracellular fluid. Examples 
of OCS are shown by red arrows in the resting platelets and zoomed in red 
squares. Green dashed circles show IONPs outside the platelets. Blue arrows 
indicate granules. 
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and Cit/2-IO nanoparticles could also be observed to bind to 
the external face of the platelet plasma membrane (Figs. 2(b) 
and 2(d); Fig. S2 in the ESM shows additional images of 
particle-treated and untreated samples). This was also consistent 
with the previous findings of Escolar et al. [8]. This rapid 
loading is important to allow the coating of the IONPs to interact 
with the contents of the OCS during the immediate phase of 
platelet activation when cytosolic Ca2+ signalling elicits changes 
in platelet activation. The combination of sustained chelation 
efficiency and rapid uptake, make the Cit/1-IO IONPs suitable 
to be used as OCS-localised Ca2+ nanochelators in thrombin- 
stimulated human platelets. This result thus provides a method 
for testing our previously-stated hypothesis that the pericellular 
accumulation of Ca2+ occurs in the OCS, and that this is 
required for full platelet function.  
There appeared to be no observable difference in the platelet 
uptake of the Cit/1-IO and Cit/2-IO particles, suggesting that 
the differences in the surface properties of these particles 
have no effect on their cellular uptake. Nanoparticle uptake 
into the OCS of human platelets will be determined by their 
ability to permeate through the pores of the OCS that link the 
invaginations of the OCS to the surface membrane of human 
platelets. This will be determined both by the number and 
size of the pores, as well as the negative surface charge of the 
platelet glycocalyx. Upon platelet activation, the pores of 
the OCS have been shown to widen upon stimulation with 
thrombin or Ca2+ ionophore [20, 21]. Additionally the number 
of pores connecting to the platelet surface has been shown to 
increase [22]. Both of these activation-dependent changes in the 
OCS pores could facilitate the easier permeation of our nano-
particles into this invaginated membrane system. Additionally, 
the surface negative charge created by glycosaminoglycans 
within the platelet glycocalyx would repel the negatively charged 
nanoparticles—this effect could be lessened upon activation 
by activation-dependent shedding of the glycocalyx [23] and 
shielding of the surface negative charge by Ca2+ binding to the 
glycocalyx [24]. Further work will be required to assess which of 
these factors most significantly affects platelet nanoparticle uptake, 
as this may provide valuable clues into how we can produce 
more effective OCS-targeted nanoparticles.  
2.4  Treatment with the Cit/1-IO nanoparticles inhibits 
thrombin-evoked rises in cytosolic calcium levels in 
human platelets  
Previous studies in our lab have demonstrated that thrombin- 
evoked platelet activation triggers a pericellular Ca2+ rise, 
which appeared to be localised within the OCS [9]. Inhibiting 
this pericellular Ca2+ rise by a number of methods has been 
consistently shown to inhibit thrombin-evoked increase in 
cytosolic calcium ([Ca2+]cyt) and thus interfere with platelet 
activation [4, 9]. Therefore, experiments were performed  
to assess whether preincubating human platelets with the 
Cit/1-IO nanoparticles could inhibit thrombin-evoked cytosolic 
Ca2+ signalling in a dose-dependent manner. 
As can be seen in the representative traces shown in Fig. 3(a), 
preincubation of platelets with Cit/1-IO caused a dose- 
dependent inhibition of thrombin-evoked Ca2+ signals elicited 
in the absence of extracellular Ca2+, with the highest IONP 
doses (equivalent to the addition of 150 μM and 300 μM Fe) 
significantly inhibiting thrombin-evoked Ca2+ rises. As shown 
in Fig. 3(b), these higher IONP doses reduced the integral of 
the thrombin-evoked rise in [Ca2+]cyt over basal to 73%  4% 
and 52%  3% of control, respectively (n = 7; P < 0.001, 
Fig. 3(b)—green and blue bars).  
 
Figure 3  Thrombin-evoked rises in [Ca2+]cyt are inhibited by preincubation 
with the Cit/1-IO Ca2+ nanoparticles, but not when incubated with the 
non-chelating Cit/2-IO or PEG-IO nanoparticles. Fura-2-loaded platelets 
were incubated with ((a) and (g)) Cit/1-IO, (c) Cit/2-IO, (e) PEG-IO 
nanoparticles at different concentration (75, 150 and 300 μM), or their 
vehicle, ddH20, for 10 min at 37 °C. Extracellular Ca2+ was then either 
chelated by addition of 1 mM EGTA ((a)–(f)), or raised to 1 mM by addition 
of further CaCl2 (g). Platelets were then stimulated with 0.5 U/mL thrombin 
(black arrows). Column bar graphs display mean % of control of the 
integrals of the thrombin-evoked rises in [Ca2+] above basal when platelets 
were incubated with (b) Cit/1-IO, (d) Cit/2-IO, (f)PEG-IO nanoparticles. 
* p < 0.001 vs. control; + p < 0.05 between IONPs. 
In contrast, preincubation of platelets with either the Cit/2-IO 
or PEG-IO nanoparticles elicited no significant effect on 
thrombin-evoked Ca2+ signals under the same condition, even 
at the highest particle concentrations used (Figs. 3(c)–3(f)). 
Control experiments in the absence of thrombin, also 
demonstrated that the Cit/1-IO nanoparticles did not directly 
activate platelets themselves. As shown in Fig. S3 in the ESM, 
addition of these IONP directly to platelets elicited no observable 
Ca2+ signal, demonstrating that the inhibitory effect observed 
previously was not due to IONP-induced activation of the 
platelets prior to thrombin addition. These data therefore 
suggest that it is not merely the presence of IONPs in the OCS 
that inhibits thrombin-evoked Ca2+ signalling, but rather the 
ability of the Cit/1-IO IONPs to chelate Ca2+ in this region. These 
results therefore demonstrate that the Cit/1-IO nanoparticles are 
able to elicit similar inhibitory effects on thrombin-evoked Ca2+ 
signalling to a range of other methods that have been utilised to 
prevent the pericellular Ca2+ accumulations [4, 9]. 
Nano Res.  
www.theNanoResearch.com∣www.Springer.com/journal/12274 | Nano Research 
5 
Further experiments assessed the ability of Cit/1-IO 
nanoparticles to inhibit thrombin-evoked cytosolic Ca2+ signals 
evoked in conditions of physiological extracellular Ca2+ con-
centration (1 mM). As can be seen in Fig. 3(g), preincubation 
with 300 μM Cit/1-IO nanoparticles significantly inhibited 
thrombin-evoked Ca2+ signals to 41.8%  4.0% of control, 
respectively (n = 6; P < 0.05). These data therefore demonstrate 
that the Cit/1-IO Ca2+ nanoparticles can significantly inhibit 
human platelet cytosolic Ca2+ signalling when stimulated in 
physiological conditions. In contrast, the PEG-IO and Cit/2-IO 
nanoparticles were found to be ineffective and unable to be 
used as Ca2+-binding agents. Subsequent experiments focused 
on assessing whether the Cit/1-IO nanoparticles functioned 
through buffering Ca2+ rises within the OCS. 
2.5  Cit/1-IO nanoparticles act as effective Ca2+ nano-
chelators as they buffer thrombin-evoked pericellular 
Ca2+ accumulations within the OCS 
Experiments were performed to assess whether the Ca2+- 
chelating Cit/1-IO nanoparticles could successfully act as Ca2+ 
nanochelators by effectively buffering the thrombin-evoked 
pericellular Ca2+ accumulation in human platelets when loaded 
into the OCS. This was initially examined by assessing the effect 
of preincubation with these IONPs on thrombin-evoked rises in 
the extracellular Ca2+ concentration ([Ca2+]ext, Fig. 4). This was 
achieved by monitoring extracellular Ca2+ accumulation using 
the cell-impermeant salt form of the Ca2+ indicators, Fluo-4 
and Rhod-5N. The different Ca2+ affinities of these indicators 
permit the assessment of Ca2+ removal in the extracellular fluid 
both in the absence of extracellular Ca2+ (Fluo-4) or in the 
presence of near-physiological levels of extracellular Ca2+ 
(300 μM; Rhod-5N).   
As can be seen in Fig. 4, preincubation of human platelets 
with Cit/1-IO nanoparticles elicited a significant reduction 
in thrombin-evoked rises in [Ca2+]ext both in the absence of  
 
Figure 4  Cit/1-IO nanoparticles act as Ca2+ nanochelators by buffering 
thrombin-evoked rises in [Ca2+]ext and [Ca2+]peri concentration. (a) Schematic 
representation of the different cellular and extracellular compartments 
monitored by the fluorescent indicators. ((b)–(d)) Washed platelet suspensions 
containing either Fluo-4 salt (b) or Rhod-5N salt (c) were preincubated 
with either 300 μM Cit/1-IO or an equivalent volume of its vehicle, 
ddH20, for 10 min at 37 °C. Extracellular Ca2+ was then either chelated by 
addition of 1 mM EGTA (b), or raised to 300 μM by addition of further 
CaCl2 (c). Platelets were then stimulated with 0.5 U/mL Thrombin 
(black arrows). (d) FFP-18-loaded human platelets were resuspended in 
supplemented HBS, and then were preincubated with either 300 μM 
Cit/1-IO or an equivalent volume of its vehicle, ddH20, for 10 min at 37 °C. 
Extracellular Ca2+ was then chelated by addition of 1 mM EGTA and 
platelets were then stimulated with 0.5 U/mL thrombin (black arrows). 
extracellular Ca2+ (48.7%  5.6% of control; n = 5; P < 0.05;  
Fig. 4(b)), as well as in the presence of near-physiological Ca2+ 
levels (50.4%  14.9% of control (n = 6; P < 0.05; Fig. 4(c)). 
These data demonstrated that the Cit/1-IO nanoparticles can 
significantly buffer thrombin-evoked rises in the Ca2+ contained 
within the extracellular fluid. However as both Fluo-4 and 
Rhod-5N are freely-diffusible through the extracellular fluid— 
they cannot distinguish Ca2+ located in the bulk extracellular 
fluid, from that contained within the lumen of the OCS or in 
the pericellular fluid surrounding the external face of the 
platelet plasma membrane. Therefore to assess pericellular 
Ca2+ rises more closely, experiments were performed using 
platelets in which the near-membrane fluorescent Ca2+ indicator, 
FFP-18, had been loaded into the extracellular face of the 
platelet plasma membrane using our previously described 
methodology [9]. As shown schematically in Fig. 4(a), this 
allows this fluorescent indicator to measure Ca2+ rises in the 
pericellular space surrounding the external face of the platelet 
plasma membrane and the contents of the OCS. Due to the 
high Ca2+ affinity of this dye, these experiments can only be 
performed in the absence of extracellular Ca2+ as it would 
become saturated at more physiological extracellular Ca2+ 
concentrations.   
As shown in Fig. 4(d), preincubation of FFP-18-loaded 
platelets with Cit/1-IO IONPs elicited a significant decrease in 
thrombin-evoked rises in [Ca2+]peri , with the integral of this 
signal reduced to 27.1%  7.9% of control (n = 5; P < 0.05).  
These data therefore indicate that the Cit/1-IO IONPs were 
able to effectively buffer thrombin-evoked rises in pericellular 
Ca2+ and thus are functional as effective Ca2+ nanochelators. 
Our previous single cell imaging of pericellular Ca2+ rises 
using Fluo-4 salt under the same conditions using the same 
methodology demonstrated that pericellular Ca2+ rises are 
not observed around the platelet surface membrane—but are 
instead found in an extracellular fluid compartment contained 
within the interior of the platelet, consistent with its presence 
in the OCS [4, 9]. These results indicate that the Cit/1-IO 
nanoparticles are able to buffer Ca2+ rises within the OCS. 
This is consistent with the TEM data in Fig. 2 that shows that 
Cit/1-IO is predominantly located inside the OCS. These 
results provide further evidence that the pericellular Ca2+ 
accumulation is localised inside the OCS, as we previously 
predicted [4, 9]. 
2.6  Treatment with the Cit/1-IO Ca2+ nanochelators 
inhibits platelet aggregation and clot retraction 
To assess the impact of the nanochelators on platelet 
functionality, experiments were performed to elucidate the 
effect of pre-incubation of human platelets with Cit/1-IO Ca2+ 
nanochelators on platelet aggregation and clot retraction. 
Conventional light transmission aggregometry utilises magnetic 
stirring to assess aggregation-induced light transmission 
changes through washed platelet and platelet-rich plasma 
samples stimulated with a platelet activator such as thrombin.  
However, due to the use of the magnetic IONPs, this was not a 
viable option in this case. Instead, experiments were performed 
utilising the alternative microplate-based aggregation assay [25]. 
This technique examines platelet aggregation by measuring 
changes in light absorbance of washed platelet samples stimulated 
with 0.5 U/mL thrombin. These studies demonstrated that 
Cit/1-IO slowed platelet aggregation to 51.0% ± 12.0% of 
control (n = 5; P < 0.05; Fig. 5), which is consistent with the 
degree of inhibition of Ca2+ signalling observed in the presence 
of 1 mM Ca2+ (Fig. 4(g)). 
Similarly, studies performed on washed platelet suspensions  
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Figure 5  Treatment with the Cit/1-IO Ca2+ nanochelators inhibits platelet 
aggregation. Washed platelet suspensions resuspended in supplemented 
HBS were treated with Cit/1-IO nanoparticles such that the [Fe] of the 
samples was 300 μM, and incubated at 37 °C for 10 min prior to stimulation 
with thrombin (0.5 U/mL). These samples were compared against a 
vehicle-treated control in which the platelet suspension was incubated 
with an equal volume of ddH2O under the same conditions. Immediately 
prior to measurement, extracellular Ca2+ concentration was raised to 1 mM 
by addition of CaCl2. Platelet aggregation were then stimulated by 
addition of 0.5 U/mL thrombin (Black arrow). This trace is representative 
of 5 independent experiments. 
assessed the ability of the various IONP formulations to 
inhibit the retraction of the formed platelet aggregate. As 
shown in Fig. 6(a), IONPs disperse evenly through the platelet 
suspension prior to stimulation giving it a notable yellow 
colour. Prolonged incubation of the IONPs with the samples 
caused no notable activation of human platelets, with platelet 
suspensions remaining stable for the 90 min observation 
period (Fig. 6(c)). Upon thrombin addition, IONPs can be 
seen to become selectively cleared from the bulk solution and 
are instead found concentrated within the formed platelet 
aggregate, in agreement with the earlier TEM data confirming 
that IONPs are only taken up by activated platelets (Fig. 6(a)). 
This result shows that thrombin stimulation triggers uptake 
of all IONPs by platelets regardless of their surface chemistry. 
Despite IONP accumulation in all platelets, Cit/1-IO was the 
only nanoparticle sample that slowed the rate of the retraction 
of the platelet aggregate, with notable differences observed 
after 30 and 45 min of thrombin stimulation (Fig. 6(b)). 
Further experiments were performed to assess the ability of 
Cit/1-IO nanoparticles to inhibit clot retraction when washed 
human platelet suspensions where suspended in HBS containing 
a physiologically-relevant extracellular Ca2+ concentration (1 mM) 
and 1 mg/mL fibrinogen. As shown in Fig. 6(d), aggregate 
retraction is significantly inhibited 40 min after thrombin 
stimulation (27.6% ± 8.1% of control, Fig. 5(d)). These data 
demonstrate that even in the presence of high extracellular 
Ca2+ concentrations found in plasma, the Cit/1-IO nanoparticles 
can still significantly inhibit platelet function through their 
ability to act as Ca2+ nanochelators within the OCS of human 
platelets.  
In summary, these results demonstrate that the OCS lumen 
is a cellular compartment that plays an active role in 
controlling human platelet activation. Thus understanding 
how thrombin-evoked changes in the contents of the OCS 
lumen may be essential to understand the processes regulating 
in vivo thrombus formation. To achieve this, IONPs could be 
further functionalised with fluorescence indicators or reporter 
enzymes to act as novel sensors of the chemical environment  
 
Figure 6  Treatment with the Cit/1-IO Ca2+ nanochelators slows thrombin- 
evoked clot retraction. Washed platelet suspensions resuspended in 
supplemented HBS were treated with Cit/1-IO, Cit/2-IO and PEG-IO 
nanoparticles such that the [Fe] of the samples was 300 μM, and incubated 
at 37 °C for 10 min prior to stimulation with thrombin (0.5 U/mL). These 
samples were compared against a vehicle-treated control in which the platelet 
suspension was incubated with an equal volume of ddH2O. (a) Representative 
clot retraction images from one experiment set and (b) mean values 
of clot retraction for each particle at 15, 30, 45 and 60 min. (c) Platelet 
exposure to IONPs in the absence of thrombin stimulation elicits no 
notable aggregation. (d) Representative clot retraction images from one 
experiment set of platelets in Ca2+ physiological conditions at 40 min after 
activation. (n = 4 for activated platelets, n = 3 for unstimulated platelets, n = 7 
for platelets with fibrin in Ca2+ physiological conditions). *p < 0.05 vs. control. 
within the OCS. Such particles would allow further investigations 
to assess how dynamic an environment the lumen of the OCS 
is upon platelet activation, and may provide additional routes to 
create OCS-targeted therapies. This finding also demonstrates 
that modifying the surface chemistry of magnetic nanoparticles 
to increase their calcium binding capacity would improve the 
biocompatibility of injected magnetic nanoparticles by preventing 
unwanted thrombotic reactions to these exogenous materials. 
3  Conclusions 
In this paper, we have demonstrated that enhancing the 
calcium-binding capacity of the surface of magnetic nanoparticles 
increases their potential to prevent the activation and 
aggregation of human platelets. The calcium-binding Cit/1-IO 
nanoparticles are able to inhibit platelet function due to their 
ability to rapidly enter the OCS upon human platelet activation, 
and act as Ca2+ nanochelators that buffer thrombin-evoked 
Ca2+ accumulations within the OCS. This has provided the 
first evidence that this cellular structure is an active regulator 
of platelet function through its ability to act as a source of Ca2+ 
that helps to maintain the cytosolic Ca2+ signals that elicit 
platelet aggregation and clot retraction. This ability of the 
Cit/1-IO nanoparticles to change the chemical environment 
within the OCS lumen has demonstrated that activation- 
dependent changes in the contents of the OCS lumen may 
play a key role in modulating human platelet function during 
thrombus formation. As little data is currently available on 
activation-induced changes in the composition of the OCS, 
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further studies using nanoparticle to sense or alter changes in 
the chemical environment within the OCS may help identify 
additional roles for this understudied structure in regulating 
normal haemostatic reactions.  
By acting as Ca2+ nanochelators, these nanoparticles are able to 
inhibit the rate of platelet aggregation and its subsequent 
retraction, providing evidence of the efficacy of an OCS- 
targeted anti-platelet therapy. A significant advantage of these 
nanoparticles is their simplicity, which would make them 
readily scalable for large-scale production. Additionally, being 
able to manipulate platelet activation by modifying the 
contents of the OCS lumen, would be particularly attractive as this 
structure is continuous with the blood plasma, thus preventing 
the need for cellular uptake. Therefore, this should make 
delivering therapeutic compounds into this region simpler than 
designing therapies that target intracellular proteins, which 
would need to permeate the cell membrane.  
Further to this, the Ca2+ nanochelators could provide 
additional clinical functions beyond that offered by traditional 
anti-platelet therapies. Firstly, the use of a magnetic nanoparticle 
would allow their recovery using external magnetic gradients, 
in a technique known as blood magnetic filtration [26]. This 
could allow provision of an anti-platelet agent to limit further 
clotting in patients undergoing surgery to treat an acute 
cardiovascular event, as blood magnetic filtration would allow 
the effects to be easily reversed prior to percutaneous coronary 
intervention or bypass surgery. Additionally, due to the selective 
uptake of the Ca2+ nanochelators by activated platelets, these 
nanoparticles could also act as contrast agents to facilitate the 
imaging of blood clots [27], as well as the filtration of emboli 
from the peripheral circulation. Lastly these Ca2+ nanochelators 
could also improve thrombolytic therapies through use of 
magnetic hyperthermia to disrupt blood clots [28]. Thus citric 
acid coated nanoparticles provide a promising prototype for 
the development of new multi-functional clinical tools to 
diagnose and treat acute cardiovascular events. 
4  Experimental 
4.1  Materials 
Fura-2/AM and FFP-18 K+ salt was from TEFlabs Inc. (Austin, 
TX). Thrombin was purchased from Merck Chemicals 
(Nottingham, UK). Fluo-5N/AM and K+ salts of Rhod-5N and 
Fluo-4 were purchased from Invitrogen (Paisley, UK). Apyrase 
was purchased from Sigma Aldrich (Gillingham, UK). All 
other reagents were of analytical grade. Commerical IONPs 
coated with citrate (referred to as Cit/2-IO) and PEG (referred 
to as PEG-IO) with amine terminal groups, respectively, were 
purchased at Chemicell-GmbH (Germany). 
4.2  Custom citric acid-coated IONP 
The IONPs denominated, Cit/1-IO, are maghemite nanometric 
particles purchased at Sigma-Aldrich as (Iron(III) oxide, < 50 nm 
particle size). The nanoparticles were coated with citric acid 
using the protocol described elsewhere [29, 30]. 
4.3  Characterisation of IONPs core size 
The core size of the IONPs was estimated by TEM using a 
JEOL JEM-1230 transmission electron microscope operated at 
100 kV. A dispersion of each IONP sample were deposited upon a 
commercial carbon-coated carbon grid (Agar Scientific) and 
left to evaporate prior to imaging. 200 IONPs were randomly 
selected from each sample and measured using ImageJ software 
to determine their size. The brightness of the TEM images were 
corrected to standardise their backgrounds. 
4.4  Iron quantification 
The iron concentration of magnetic nanoparticles dispersions 
was determined using the Ferrozine method. IONPs were 
digested in 6 M nitric acid at 60 °C overnight. Afterwards, 
digested samples were incubated in 3.3 M hydroxylamine 
hydrochloride at room temperature for 2.5 h to reduce Fe3+ 
cations to Fe2+. Finally, samples were incubated in dark in a 
solution containing 1.75 mM ferrozin and 0.1 mM HEPES for 
1 hour at room temperature, and their absorbance were measured 
in a plate reader at 562 nm. The absorbance was then compared 
with a calibration curve obtained from an iron solution 
standard. 
4.5  Hydrodynamic size and zeta potential measurements 
The hydrodynamic size (DH) of the IONP samples were 
measured by DLS in a Zetasizer Nano (Malvern) in ddH2O. A 
laser emitting red light at 633 nm acted as energy source, 173° 
was the angle between the sample and the detector. Measurements 
were performed in 1 mL disposable cuvette. Zeta potential was 
measured using the same instrument in a disposable capillary 
cuvette. Measurements were performed at an iron concentration 
of 0.02 mg/mL. 
4.6  Ca2+ buffering capability of IONPs 
300 M of the IONPs were dispersed in 1.2 mL ddH2O containing 
250 M EGTA and 3 M Fura-2 K+ salt and incubated in 
cuvettes for 10 min at 37 C. The fluorescence intensity of the 
suspension was recorded at 37 °C using a Cairn Research Spectro-
photometer (Cairn Research, Faversham, UK) using excitation 
wavelengths (λex) of 340 and 380 nm, and emission wavelengths 
(λem) of 515 nm. Variations in 340/380 nm ratio were monitored 
upon the stepwise addition of CaCl2 to the dispersion and 
normalised to the saturation 340/380 nm ratio value for each 
sample. The free [Ca2+] concentration of the buffered solution was 
calculated using MaxChelator software (Standford University, 
USA). 
4.7  Preparation of washed human platelet suspensions 
This study was approved by the Keele University Research 
Ethics Committee. Blood was donated by healthy volunteers 
who had provided written informed consent. Blood was 
collected by venepuncture and mixed with one-sixth volume 
of acid citrate dextrose (ACD) anticoagulant (85 mM sodium 
citrate, 78 mM citric acid, and 111 mM D-glucose). Platelet-rich 
plasma (PRP) and washed platelets were prepared according 
to previously-published protocols [9]. PRP was prepared by 
centrifugation of anticoagulated blood for 8 min at 1,500g, to 
which 100 μM Aspirin and 0.1 U/mL apyrase were then added. 
Washed platelet suspensions were obtained by centrifugation 
of PRP at 350g for 20 min, and the platelet pellet was then 
resuspended in a HEPES-buffered saline (HBS; pH 7.4, 145 mM 
NaCl, 10 mM HEPES, 10 mM d-glucose, 5 mM KCl, and 1 mM 
MgSO4) supplemented on the day with 1 mg/mL bovine serum 
albumin, 10 mM glucose, 0.1 U/mL apyrase, and 200 μM CaCl2 
(Sup-HBS). 
4.8  Subcellular localisation of platelet-associated IONPs 
Platelets suspended in sup-HBS were incubated with each two 
citric acid coated IONPs (Cit/1-IO and Cit/2-IO, [Fe] = 300 μM) 
at 37 °C for 10 min. Immediately after, a part of platelets 
suspensions were treated with of EGTA (1 mM) and stimulated 
with thrombin (0.5 u/mL) in analogous manner to [Ca2+]Cyt 
measurements. 1 min after the activation, all platelet samples 
were fixed following the protocol described by White et al. [8].  
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Briefly, platelet suspensions were mixed with equal volume of 
White’s buffer containing 0.01% of EM grade glutaraldehyde 
(GTA) (v/v) and incubated for 15 min at 37 C. Immediately 
after, this pre-fixation buffer was substituted by centrifugation 
for White’s buffer containing 2.5% GTA (v/v) and platelet 
suspensions were kept at 4 °C for 1 h. Following the fixation, 
samples were washed 3 times in 0.1 mM sodium cacodylate 
buffer containing 2 mM calcium chloride (pH 7.4). In between 
each wash the samples were centrifuged before removing the 
excess buffer and then resuspended in the newly added buffer. 
The samples were then post fixed in 0.1% OsO4 in the same 
buffer for 1 hour at room temperature before being washed 
again 3 times with the same buffer using the same method as 
previously. Samples were subsequently suspended in 3% agar (w/v) 
aqueous solution to provide a suitable media to support the 
samples through further processing. The samples in agar were 
then dehydrated through a graded ethanol series of increasing 
concentration (70%, 80%, 90%, 100% and Dry 100%) for 15 min 
in each concentration. Finally, the samples were infiltrated 
through increasing concentrations of ethanol to SPURR 
resin before having 3 changes of pure SPURR resin and being 
embedded in moulds with fresh prepared SPURR resin, and 
then polymerised at 60 ° C for 16 h. Ultrathin section of 
70 nm thickness were then taken using a Leica Ultracut UCT 
ultramicrotome onto 200 mesh thin bar copper grids using  
a diamond knife. The sections were examined using a JEOL 
JEM-1230 transmission electron microscope operated at 100 kV. 
A digital Software Imaging System (SIS) Megaview III camera 
was used to capture electron micrographs with SIS iTEM 
software. Brightness of the TEM images was corrected to 
standardize their background. 
4.9  Monitoring of thrombin-evoked rises in extracellular 
Ca2+ concentration 
The release of Ca2+ to the extracellular medium in the 
absence of extracellular Ca2+ was monitored in washed platelet 
suspensions resuspended in a sup-HBS containing 1 mM 
EGTA, by addition of 2.5 μM Fluo-4 K+ salt to the suspension 
immediately prior to the start of experiments. Fluorescence 
were recorded as for Fura-2 above but with λex = 485 nm 
and λem between 515 and 565 nm. The release of Ca2+ to the 
extracellular medium in the presence of 300 μmol/L extracellular 
Ca2+ was monitored by addition of 2.5 μmol/L Rhod-5N to 
washed platelet suspensions immediately prior to the start of 
experiments. Fluorescence was monitored as for Fura-2 above 
but with excitation at 550 nm and collecting emitted light of 
wavelengths between 570 and 640 nm. Fluo-4 and Rhod-5N 
data were calibrated to measure the total Ca2+ concentration 
(buffered and free Ca2+) in the extracellular medium as previously 
described [3]. 
4.10  Monitoring of thrombin-evoked rises in pericellular 
Ca2+ concentration 
Thrombin-evoked changes in [Ca2+]Peri was monitored in 
platelets loaded with FFP-18 salt using a method to specifically 
label extracellular membrane [9]. Sup-HBS platelets suspensions 
were treated with FFP-18 (5 μM) for 5 min at room temperature. 
Later, platelets were split in 1 mL aliquots to which 250 μL  
of ACD was added. Platelets were centrifuged at 8,000g for 
30 s and supernatant was removed and the pelleted cells were 
resuspended in sup-HBS. Fluorescence was recorded as for 
Fura-2 above. Changes in [Ca2+]peri were monitored using the 
340/380 nm fluorescence ratio. 
4.11  Monitoring thrombin-evoked changes in cytosolic 
Ca2+ concentration  
Thrombin-evoked changes in cytosolic Ca2+ concentration 
([Ca2+]Cyt) were estimated using Fura-2-loaed human platelets. 
PRP was incubated with Fura-2/AM (2 μM) for 45 min at 37 °C. 
PRP was then centrifuged at 350g for 20 min, and the platelets 
were then re-suspended in sup-HBS. Fluorescence was recorded 
from 1.2 mL stirred aliquots of platelet suspension at 37 °C 
with a Cairn Research Spectrophotometer (Cairn Research, 
Faversham, UK) using λex of 340 and 380 nm, and λem of 515 nm. 
Changes in [Ca2+]cyt were calibrated using the methodology of 
Grynkiewicz et al. [31].  
4.12  Quantification of thrombin-evoked rises in 
[Ca2+]Cyt, [Ca2+]Peri and [Ca2+]Ext 
Quantification of thrombin-evoked rises in [Ca2+]Cyt, [Ca2+]Peri 
and [Ca2+]Ext were quantified by integration of the change in 
fluorescence records above basal fluorescence with respect to 
time for 3 min after thrombin addition. Basal fluorescence was 
defined as the mean [Ca2+] recorded for 10 s prior to thrombin 
addition (as shown schematically in Fig. S4 in the ESM). 
4.13  Platelet aggregometry 
Washed human platelet suspension resuspended in supplemented 
HBS were preincubated with either 300 μM Cit/1-IO nanoparticles 
or an equivalent volume of ddH20. The external Ca2+ concen-
tration was then raised to 1 mM. 100 μL aliquots were then 
dispensed into 96-well plates. Light absorbance was measured 
on BioTek Synergy microplate reader set up to keep plates at 
37 °C. Basal absorbance was measured every 10 s for 5 min to 
allow for measurement of maximum absorbance of both 
samples (Amax). Platelets were then stimulated by addition of 
0.5 U/mL thrombin and light absorbance read every 10 s for a 
further 10 min. A minimum absorbance (Amin) was measured 
simultaneously from a platelet-free supplemented HBS sample 
to which 300 μM Cit/1-IO nanoparticles or an equivalent 
volume of ddH20 had been added. Data were normalised to % 
optical density using the following formula 
Optical density min
max min
% 100 A A
A A
-= ⋅ -         (1) 
The maximum decrease in optical density obtained during 
the experiment was compared between samples.  
4.14  Clot retraction measurements 
1.2 mL of washed platelets suspensions resuspended in 
supplemented HBS were aliquoted into cuvettes and 
incubated with the different IONPs ([Fe] = 300 μM) at 37 °C 
for 10 min. Platelets were then stimulated by the addition of 
0.5 U/mL thrombin and clot formation and retraction was 
then monitored taking photos every 15 min for 90 min at 
room temperature. Images were later analysed with ImageJ by 
calculation of the relative area occupied by the clot in the front 
face of cuvettes.  
4.15  Statistical analysis 
Blood from two to five donors were used in each experiment. 
n signifies independently tested platelet samples. Values are 
reported as mean ± SEM, except for IONPs physicochemical 
and morphological characterisation, which are mean ± SD.  
Statistical significance was assessed by one-way ANOVA with a 
post hoc Tukey test of repeated measurements. A P < 0.05 was 
considered significant. 
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